Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 12/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | NQO2 | P16083 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7295488 | 0.86 | MTNR1A (0.56) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL12013659 | 0.84 | HTR2A (0.65) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL12550704 | 0.83 | HTR2A (0.63) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL28193568 | 0.83 | HTR2A (0.63) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL3327733 | 0.83 | HTR2A (0.63) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL3279789 | 0.83 | HTR2A (0.63) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL827963 | 0.81 | HTR2A (0.70) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL17188138 | 0.81 | HTR2A (0.57) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL14714813 | 0.80 | HTR2A (0.68) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL1882845 | 0.80 | HTR2A (0.68) | HTR2AMTNR1AMTNR1BHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146110-A | N-difluoromethyl carbonyl compound and preparation method thereof | 中山大学附属第一医院 | 2024-06-07 | — | — | CN | claimed |
| US-8653281-B2 | Process for the manufacture of agomelatine and its intermediate | NHWA PHARMA. CORPORATION (CN) | 2014-02-18 | — | — | US | claimed |
| CN-103501777-A | Pharmaceutically acceptable cocrystal of N- [2- (7-methoxy-1-naphthyl) ethyl ] acetamide and preparation method thereof | ZENTIVA KS | 2014-01-08 | — | — | CN | claimed |
| EP-2322508-B1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA PHARMA CORP (CN) | 2013-01-02 | — | — | EP | claimed |
| US-20110130571-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA PHARMA. CORPORATION (CN) | 2011-06-02 | — | — | US | claimed |
| EP-2322508-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA Pharma. Corporation (CN) | 2011-05-18 | — | — | EP | claimed |
| CN-118146110-A | N-difluoromethyl carbonyl compound and preparation method thereof | 中山大学附属第一医院 | 2024-06-07 | — | — | CN | disclosed |
| EP-3134392-A1 | SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2017-03-01 | — | — | EP | disclosed |
| WO-2015158313-A1 | SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-22 | — | — | WO | disclosed |
| CN-102161658-B | N-(naphthoxyalkyl)heteroarylpiperidine compounds and preparation method and applications thereof | ZHEJIANG HUAHAI PHARM CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8653281-B2 | Process for the manufacture of agomelatine and its intermediate | NHWA PHARMA. CORPORATION (CN) | 2014-02-18 | — | — | US | disclosed |
| CN-103501777-A | Pharmaceutically acceptable cocrystal of N- [2- (7-methoxy-1-naphthyl) ethyl ] acetamide and preparation method thereof | ZENTIVA KS | 2014-01-08 | — | — | CN | disclosed |
| EP-2322508-B1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA PHARMA CORP (CN) | 2013-01-02 | — | — | EP | disclosed |
| US-20110130571-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA PHARMA. CORPORATION (CN) | 2011-06-02 | — | — | US | disclosed |
| EP-2322508-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | NHWA Pharma. Corporation (CN) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130571-A1 | PROCESS FOR THE MANUFACTURE OF AGOMELATINE AND ITS INTERMEDIATE | PNMT, INMT, PTMA | HTR2A 1021/4885MTNR1A 184/4885MTNR1B 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.